CA3018155A1 - Combination therapy for the treatment of acute myeloid leukemia - Google Patents
Combination therapy for the treatment of acute myeloid leukemia Download PDFInfo
- Publication number
- CA3018155A1 CA3018155A1 CA3018155A CA3018155A CA3018155A1 CA 3018155 A1 CA3018155 A1 CA 3018155A1 CA 3018155 A CA3018155 A CA 3018155A CA 3018155 A CA3018155 A CA 3018155A CA 3018155 A1 CA3018155 A1 CA 3018155A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- salt
- acute myeloid
- myeloid leukemia
- ylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662314700P | 2016-03-29 | 2016-03-29 | |
| US62/314700 | 2016-03-29 | ||
| US201662368343P | 2016-07-29 | 2016-07-29 | |
| US62/368343 | 2016-07-29 | ||
| PCT/JP2017/012293 WO2017170348A1 (en) | 2016-03-29 | 2017-03-27 | Combination therapy for the treatment of acute myeloid leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3018155A1 true CA3018155A1 (en) | 2017-10-05 |
Family
ID=59965623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3018155A Abandoned CA3018155A1 (en) | 2016-03-29 | 2017-03-27 | Combination therapy for the treatment of acute myeloid leukemia |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190117649A1 (enExample) |
| EP (1) | EP3436014A4 (enExample) |
| JP (1) | JP2019512495A (enExample) |
| KR (1) | KR20180124055A (enExample) |
| CN (1) | CN108883109A (enExample) |
| BR (1) | BR112018069111A2 (enExample) |
| CA (1) | CA3018155A1 (enExample) |
| MX (1) | MX2018011975A (enExample) |
| RU (1) | RU2018134167A (enExample) |
| WO (1) | WO2017170348A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| EP3928780A4 (en) * | 2019-02-22 | 2022-12-07 | Hanmi Pharm. Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING A FLT3 INHIBITOR AND HYPOMETHYLATING AGENT FOR THE TREATMENT OF ACUTE MYELOIC LEUKEMIA |
| BR112021016522A2 (pt) * | 2019-02-22 | 2021-10-26 | Hanmi Pharm. Co., Ltd. | Composição farmacêutica para o tratamento da leucemia mieloide aguda |
| KR20200102948A (ko) | 2019-02-22 | 2020-09-01 | 한미약품 주식회사 | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 |
| PL3949952T3 (pl) * | 2019-04-03 | 2024-10-14 | Astellas Pharma Inc. | Kompozycja farmaceutyczna |
| EP3991733A4 (en) | 2019-06-27 | 2023-07-05 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents |
| MX2022004555A (es) * | 2019-10-14 | 2022-07-21 | Astrazeneca Ab | Terapia de combinacion para tratar una neoplasia maligna hematologica. |
| CN114828842A (zh) * | 2019-10-21 | 2022-07-29 | 理森制药股份公司 | 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物 |
| KR20230056331A (ko) * | 2021-10-20 | 2023-04-27 | 한미약품 주식회사 | 급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합 |
| WO2023129667A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| KR102559124B1 (ko) | 2022-08-25 | 2023-07-26 | 주식회사 엔젠바이오 | Flt3 유전자 증폭용 조성물 및 이의 용도 |
-
2017
- 2017-03-27 EP EP17774885.2A patent/EP3436014A4/en not_active Withdrawn
- 2017-03-27 WO PCT/JP2017/012293 patent/WO2017170348A1/en not_active Ceased
- 2017-03-27 CN CN201780021735.4A patent/CN108883109A/zh active Pending
- 2017-03-27 JP JP2018548236A patent/JP2019512495A/ja active Pending
- 2017-03-27 US US16/089,603 patent/US20190117649A1/en not_active Abandoned
- 2017-03-27 RU RU2018134167A patent/RU2018134167A/ru not_active Application Discontinuation
- 2017-03-27 MX MX2018011975A patent/MX2018011975A/es unknown
- 2017-03-27 CA CA3018155A patent/CA3018155A1/en not_active Abandoned
- 2017-03-27 KR KR1020187028124A patent/KR20180124055A/ko not_active Withdrawn
- 2017-03-27 BR BR112018069111-9A patent/BR112018069111A2/pt not_active Application Discontinuation
-
2020
- 2020-07-30 US US16/943,379 patent/US20200360372A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018069111A2 (pt) | 2019-03-19 |
| CN108883109A (zh) | 2018-11-23 |
| RU2018134167A3 (enExample) | 2020-06-30 |
| US20200360372A1 (en) | 2020-11-19 |
| JP2019512495A (ja) | 2019-05-16 |
| RU2018134167A (ru) | 2020-04-29 |
| EP3436014A4 (en) | 2019-11-27 |
| MX2018011975A (es) | 2019-01-15 |
| US20190117649A1 (en) | 2019-04-25 |
| EP3436014A1 (en) | 2019-02-06 |
| KR20180124055A (ko) | 2018-11-20 |
| WO2017170348A1 (en) | 2017-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200360372A1 (en) | Combination therapy for the treatment of acute myeloid leukemia | |
| Ghiaur et al. | Mechanisms of resistance to FLT3 inhibitors and the role of the bone marrow microenvironment | |
| Khandelwal et al. | Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients | |
| Olson et al. | Megakaryocytes promote murine osteoblastic HSC niche expansion and stem cell engraftment after radioablative conditioning | |
| Andersson et al. | Clofarabine±fludarabine with once daily iv busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS | |
| EP3493812B1 (en) | Combinations of imetelstat and venetoclax for the treatment of acute myeloid leukaemia | |
| US20030147813A1 (en) | Method for treating chronic myelogenous leukemia | |
| Virchis et al. | Fludarabine, cytosine arabinoside, granulocyte‐colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes | |
| Schwestermann et al. | Contribution of the tumor microenvironment to metabolic changes triggering resistance of multiple myeloma to proteasome inhibitors | |
| JP2009102408A (ja) | ホモハリングトニンを単独で、または他の薬剤と組み合わせて用いる、ｓｔｉ５７１に耐性または不耐性の慢性骨髄性白血病の治療 | |
| Davids et al. | Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies | |
| Maiti et al. | How we incorporate venetoclax in treatment regimens for acute myeloid leukemia | |
| Czajczynska et al. | Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma | |
| WO2018015526A1 (en) | Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof | |
| Hao et al. | Metabolic reprogramming and immune regulation in acute myeloid leukemia | |
| Karp et al. | Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features | |
| Glaviano et al. | Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia | |
| CN115120724A (zh) | 治疗再生障碍性贫血的方法和药物组合物 | |
| Chiesa et al. | Unpredictability of intravenous busulfan pharmacokinetics in children undergoing hematopoietic stem cell transplantation for advanced beta thalassemia: limited toxicity with a dose-adjustment policy | |
| US20190183893A1 (en) | Low dose of sildenafil as an antitumor drug | |
| Shao et al. | Cyclosporin combined with levamisole for refractory or relapsed severe aplastic anaemia. | |
| Ottmann et al. | Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts | |
| EP3487499A1 (en) | Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof | |
| JP7186731B2 (ja) | 血液ガンのためのｍｃｌ－１阻害剤と標準治療処置との組み合わせ、その使用及び医薬組成物 | |
| Andreola et al. | Who should be really considered as a poor mobilizer in the plerixafor era? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20230627 |